{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:00:14Z","timestamp":1794859214514,"version":"4.9.1"},"reference-count":87,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin\u2019s lymphoma that generally affects older individuals and continues to have one of the worst outcomes of all the lymphomas. Over the last decade, there has been a widespread adoption of cytarabine-based therapy in younger patients, and the incorporation of rituximab into chemotherapeutic regimens has become an evidence-based standard of care. However MCL remains a largely incurable disease, and following relapse, it can be a challenge to manage. Although it is possible to define prognosis reliably, there are, as yet, no clear diagnostic or response-adjusted parameters that can help to guide therapeutic decisions. However, there are a number of highly active targeted therapies that are moving into the clinic that are set to transform the therapeutic paradigm for this disease in the very near future. This review will explore the molecular pathogenesis of MCL and the current and evolving therapeutic strategies for this disease.<\/jats:p>","DOI":"10.1182\/blood-2014-05-521898","type":"journal-article","created":{"date-parts":[[2014,12,12]],"date-time":"2014-12-12T04:29:29Z","timestamp":1418358569000},"page":"48-55","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":157,"title":["Mantle cell lymphoma: evolving management strategies"],"prefix":"10.1182","volume":"125","author":[{"given":"Elias","family":"Campo","sequence":"first","affiliation":[{"name":"Hematopathology Section, Department of Pathology, Hospital Clinic, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer, University of Barcelona, Barcelona, Spain; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Rule","sequence":"additional","affiliation":[{"name":"Plymouth University Peninsula Schools of Medicine and Dentistry and Derriford Hospital, Plymouth, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"10","key":"2019111819573980000_B1","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1172\/JCI61272","article-title":"Molecular pathogenesis of mantle cell lymphoma.","volume":"122","author":"Jares","year":"2012","journal-title":"J Clin Invest"},{"issue":"20","key":"2019111819573980000_B2","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-12-1615","article-title":"Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features.","volume":"72","author":"Navarro","year":"2012","journal-title":"Cancer Res"},{"issue":"4","key":"2019111819573980000_B3","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/0008-5472.CAN-09-3419","article-title":"Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma.","volume":"70","author":"Fern\u00e0ndez","year":"2010","journal-title":"Cancer Res"},{"issue":"8","key":"2019111819573980000_B4","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1038\/leu.2012.72","article-title":"Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease.","volume":"26","author":"Royo","year":"2012","journal-title":"Leukemia"},{"issue":"2","key":"2019111819573980000_B5","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1182\/blood-2007-06-093401","article-title":"Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma.","volume":"111","author":"Ek","year":"2008","journal-title":"Blood"},{"issue":"11","key":"2019111819573980000_B6","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3324\/haematol.2009.010264","article-title":"SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype.","volume":"94","author":"Mozos","year":"2009","journal-title":"Haematologica"},{"issue":"12","key":"2019111819573980000_B7","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1182\/blood-2012-06-438937","article-title":"SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma.","volume":"121","author":"Vegliante","year":"2013","journal-title":"Blood"},{"issue":"8","key":"2019111819573980000_B8","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2012-08-452284","article-title":"CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma.","volume":"121","author":"Salaverria","year":"2013","journal-title":"Blood"},{"issue":"8","key":"2019111819573980000_B9","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1182\/blood-2005-10-4079","article-title":"The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma.","volume":"107","author":"Katzenberger","year":"2006","journal-title":"Blood"},{"issue":"45","key":"2019111819573980000_B10","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.","volume":"110","author":"Be\u00e0","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"19","key":"2019111819573980000_B11","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1182\/blood-2013-07-517177","article-title":"The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells.","volume":"123","author":"Zhang","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2019111819573980000_B12","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1182\/blood-2011-11-391474","article-title":"Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma.","volume":"119","author":"Kridel","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111819573980000_B13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-\u03baB-targeted treatment strategies for mantle cell lymphoma.","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat Med"},{"issue":"1","key":"2019111819573980000_B14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ccr.2013.12.011","article-title":"Unlocking new therapeutic targets and resistance mechanisms in mantle cell lymphoma.","volume":"25","author":"Colomer","year":"2014","journal-title":"Cancer Cell"},{"issue":"1","key":"2019111819573980000_B15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.","volume":"117","author":"P\u00e9rez-Gal\u00e1n","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2019111819573980000_B16","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111819573980000_B17","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.3324\/haematol.2009.019745","article-title":"Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma.","volume":"95","author":"Baran-Marszak","year":"2010","journal-title":"Haematologica"},{"issue":"28","key":"2019111819573980000_B18","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111819573980000_B19","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","article-title":"Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.","volume":"150","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111819573980000_B20","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2141.2011.08958.x","article-title":"Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi.","volume":"156","author":"Merli","year":"2012","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111819573980000_B21","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/annonc\/mdt070","article-title":"A phase II multicenter trial of hyperCVAD MTX\/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213.","volume":"24","author":"Bernstein","year":"2013","journal-title":"Ann Oncol"},{"issue":"7","key":"2019111819573980000_B22","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2019111819573980000_B23","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","article-title":"Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.","volume":"158","author":"Geisler","year":"2012","journal-title":"Br J Haematol"},{"key":"2019111819573980000_B24","author":"Hermine"},{"issue":"9","key":"2019111819573980000_B25","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","article-title":"Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111819573980000_B26","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3109\/10428190109097721","article-title":"Cyclophosphamide\/fludarabine (CF) is active in the treatment of mantle cell lymphoma.","volume":"42","author":"Cohen","year":"2001","journal-title":"Leuk Lymphoma"},{"issue":"27","key":"2019111819573980000_B27","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin\u2019s lymphoma.","volume":"26","author":"Robinson","year":"2008","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111819573980000_B28","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma.","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"issue":"9873","key":"2019111819573980000_B29","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"19","key":"2019111819573980000_B30","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Open-label, randomized, noninferiority study of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of advanced indolent NHL or MCL: the BRIGHT study.","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2019111819573980000_B31","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","article-title":"European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.","volume":"18","author":"Foran","year":"2000","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111819573980000_B32","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/hon.2900070505","article-title":"Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis.","volume":"7","author":"Meusers","year":"1989","journal-title":"Hematol Oncol"},{"issue":"3","key":"2019111819573980000_B33","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3109\/10428194.2010.534518","article-title":"Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen.","volume":"52","author":"Sachanas","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2019111819573980000_B34","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/cncr.23537","article-title":"Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group.","volume":"113","author":"Inwards","year":"2008","journal-title":"Cancer"},{"issue":"8","key":"2019111819573980000_B35","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2004-03-1091","article-title":"Antitumor activity of rituximab plus thalidomide in patients with relapsed\/refractory mantle cell lymphoma.","volume":"104","author":"Kaufmann","year":"2004","journal-title":"Blood"},{"issue":"10","key":"2019111819573980000_B36","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.bbmt.2010.04.006","article-title":"Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.","volume":"16","author":"Cook","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"2019111819573980000_B37","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1200\/JCO.2003.05.501","article-title":"Nonablative allogeneic stem-cell transplantation for advanced\/recurrent mantle-cell lymphoma.","volume":"21","author":"Khouri","year":"2003","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111819573980000_B38","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/annonc\/mdu097","article-title":"Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT).","volume":"25","author":"Dietrich","year":"2014","journal-title":"Ann Oncol"},{"issue":"9","key":"2019111819573980000_B39","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1093\/annonc\/mdl127","article-title":"Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network.","volume":"17","author":"Kahl","year":"2006","journal-title":"Ann Oncol"},{"issue":"23","key":"2019111819573980000_B40","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1200\/JCO.2012.46.9585","article-title":"Obinutuzumab (GA101) monotherapy in relapsed\/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study.","volume":"31","author":"Morschhauser","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111819573980000_B41","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/bjh.12769","article-title":"Ofatumumab monotherapy in relapsed\/refractory mantle cell lymphoma\u2014a phase II trial.","volume":"165","author":"Furtado","year":"2014","journal-title":"Br J Haematol"},{"issue":"31","key":"2019111819573980000_B42","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1200\/JCO.2009.21.8545","article-title":"Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma.","volume":"27","author":"Wang","year":"2009","journal-title":"J Clin Oncol"},{"issue":"25","key":"2019111819573980000_B43","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2012.42.2444","article-title":"Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499.","volume":"30","author":"Smith","year":"2012","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019111819573980000_B44","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1182\/blood-2013-12-541953","article-title":"Nordic MCL-3 study: BEAM\/C conditioning intensified with 90Y-Ibritumomab-Tiuxetan in responding non-CR patients followed by autologous transplant in mantle cell lymphoma.","volume":"123","author":"Kolstad","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2019111819573980000_B45","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3324\/haematol.2013.088377","article-title":"First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group.","volume":"98","author":"Arranz","year":"2013","journal-title":"Haematologica"},{"issue":"26","key":"2019111819573980000_B46","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1200\/JCO.2008.21.3116","article-title":"Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.","volume":"27","author":"Andersen","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111819573980000_B47","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1200\/JCO.2012.45.9842","article-title":"Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation.","volume":"31","author":"Visco","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111819573980000_B48","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.3109\/10428194.2012.672736","article-title":"Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective study by the Finnish Lymphoma Group.","volume":"53","author":"R\u00e4ty","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"30","key":"2019111819573980000_B49","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"issue":"23","key":"2019111819573980000_B50","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"issue":"29","key":"2019111819573980000_B51","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.","volume":"31","author":"Goy","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111819573980000_B52","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","article-title":"Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study.","volume":"12","author":"Ansell","year":"2011","journal-title":"Lancet Oncol"},{"issue":"1","key":"2019111819573980000_B53","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2141.2010.08315.x","article-title":"Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma.","volume":"151","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111819573980000_B54","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","article-title":"Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.","volume":"29","author":"Ruan","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111819573980000_B55","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2013-08-523845","article-title":"Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).","volume":"123","author":"Chang","year":"2014","journal-title":"Blood"},{"issue":"19","key":"2019111819573980000_B56","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1002\/cncr.24518","article-title":"Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA).","volume":"115","author":"Ribrag","year":"2009","journal-title":"Cancer"},{"issue":"3","key":"2019111819573980000_B57","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/sj.leu.2404511","article-title":"Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.","volume":"21","author":"Weigert","year":"2007","journal-title":"Leukemia"},{"issue":"5","key":"2019111819573980000_B58","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1080\/10428190902856790","article-title":"A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study.","volume":"50","author":"Weigert","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2019111819573980000_B59","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1365-2141.2011.08820.x","article-title":"VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study.","volume":"155","author":"Chang","year":"2011","journal-title":"Br J Haematol"},{"issue":"7","key":"2019111819573980000_B60","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial.","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"},{"issue":"2","key":"2019111819573980000_B61","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/bjh.12008","article-title":"Single-agent lenalidomide in relapsed\/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences.","volume":"159","author":"Eve","year":"2012","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111819573980000_B62","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/bjh.12780","article-title":"Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study.","volume":"165","author":"Wang","year":"2014","journal-title":"Br J Haematol"},{"issue":"22","key":"2019111819573980000_B63","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":"Results of a phase I study of idelalisib, a PI3K\u03b4 inhibitor, in patients with relapsed or refractory mantle cell lymphoma (MCL).","volume":"123","author":"Kahl","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2019111819573980000_B64","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nri3487","article-title":"New insights into pre-BCR and BCR signalling with relevance to B cell malignancies.","volume":"13","author":"Rickert","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2019111819573980000_B65","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies.","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111819573980000_B66","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11899-013-0188-8","article-title":"Bruton\u2019s tyrosine kinase (BTK) inhibitors in clinical trials.","volume":"9","author":"Burger","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"issue":"2","key":"2019111819573980000_B67","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1586\/17474086.2014.889561","article-title":"Risk factors for etiology and prognosis of mantle cell lymphoma.","volume":"7","author":"Wang","year":"2014","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"2019111819573980000_B68","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"8","key":"2019111819573980000_B69","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma.","volume":"27","author":"Martin","year":"2009","journal-title":"J Clin Oncol"},{"issue":"16","key":"2019111819573980000_B70","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"issue":"10","key":"2019111819573980000_B71","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/ajh.22126","article-title":"Utility of positron emission tomography scans in mantle cell lymphoma.","volume":"86","author":"Hosein","year":"2011","journal-title":"Am J Hematol"},{"issue":"9","key":"2019111819573980000_B72","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s00259-010-1469-2","article-title":"Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group.","volume":"37","author":"Bodet-Milin","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2019111819573980000_B73","article-title":"Is there a role for therapy response assessment with FDG-PET\/CT in Mantle cell Lymphoma?","author":"Kedmi","journal-title":"Leuk Lymphoma"},{"issue":"14","key":"2019111819573980000_B74","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1002\/cncr.26731","article-title":"Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD.","volume":"118","author":"Mato","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"2019111819573980000_B75","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3816\/CLM.2008.n.019","article-title":"[18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma.","volume":"8","author":"Gill","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"issue":"7","key":"2019111819573980000_B76","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","article-title":"Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"issue":"1","key":"2019111819573980000_B77","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","article-title":"CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte.","volume":"121","author":"Delarue","year":"2013","journal-title":"Blood"},{"issue":"36","key":"2019111819573980000_B78","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1200\/JCO.2009.22.2554","article-title":"Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.","volume":"27","author":"Damon","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111819573980000_B79","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1365-2141.2008.07498.x","article-title":"High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients.","volume":"144","author":"van \u2019t Veer","year":"2009","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111819573980000_B80","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1365-2141.2005.05777.x","article-title":"Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma.","volume":"131","author":"Bauwens","year":"2005","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111819573980000_B81","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.bbmt.2014.01.004","article-title":"Phase I\/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.","volume":"20","author":"William","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2019111819573980000_B82","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/annonc\/mdr450","article-title":"Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS.","volume":"23","author":"Houot","year":"2012","journal-title":"Ann Oncol"},{"issue":"2","key":"2019111819573980000_B83","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3109\/10428194.2011.608445","article-title":"A phase I study evaluating ibritumomab tiuxetan (Zevalin\u00ae) in combination with bortezomib (Velcade\u00ae) in relapsed\/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma.","volume":"53","author":"Beaven","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2019111819573980000_B84","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3324\/haematol.2011.041392","article-title":"Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.","volume":"96","author":"Lamm","year":"2011","journal-title":"Haematologica"},{"issue":"3","key":"2019111819573980000_B85","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3109\/10428194.2010.546015","article-title":"A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).","volume":"52","author":"Kouroukis","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2019111819573980000_B86","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2141.2010.08340.x","article-title":"Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstr\u00f6m macroglobulinaemia.","volume":"151","author":"Agathocleous","year":"2010","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111819573980000_B87","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1002\/cncr.25792","article-title":"Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.","volume":"117","author":"Baiocchi","year":"2011","journal-title":"Cancer"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/125\/1\/48\/1383125\/48.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/125\/1\/48\/1383125\/48.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T20:50:46Z","timestamp":1717620646000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/125\/1\/48\/33914\/Mantle-cell-lymphoma-evolving-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,1]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2014-05-521898","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,1]]}}}